

Appointment of Managing Director

Resonance Health Ltd (ASX: RHT) ("Resonance Health" or "Company") is pleased to advise that from 2 July 2021, Mr. Mitchell Wells will transition to the role of Managing Director of Resonance Health, from his current role as Executive Director.

Mr. Wells commenced working with Resonance Health in April 2017. He initially provided strategy, contract, and corporate advisory services and in early 2018 he was invited to join the Board of Directors. He has served as a Director and a consultant since February 2018.

Mr. Wells worked closely with Ms. Laws during her tenure as CEO and he was appointed as fulltime Executive Director upon the Board receiving notice of Ms. Laws' resignation (see ASX announcement dated 4 June 2021, "*Resignation of CEO & Management Changes*"). He is intimately involved in the Company's commercial contracts and negotiations, and is familiar with the Company's initiatives and projects, including the regulatory frameworks in which it must operate as a manufacturer of medical devices.

Mr. Wells is well known to the Company's personnel and to many shareholders. He has worked as a senior executive and as a Director of several ASX and US Nasdaq listed public companies. He has international project management and legal experience, having worked as a project manager and as a corporate and contracts consultant in Australia, the USA, and the United Kingdom.

Mr. Wells' career started as a lawyer working in law firms before transitioning to an executive role in the UK as a founding executive of London's successful bid to host the 2012 Olympic & Paralympic Games. He then worked as a project manager on the GBP600 million redevelopment of The O2 Arena precinct in London, regarded by many as Europe's most successful entertainment precinct.

Mitchell returned to Australia in 2008 to take up the role of COO, and ultimately CEO, of ASX listed Amadeus Energy Ltd, which was acquired by US based Lonestar Resources Inc. He then facilitated Lonestar's listing on the US Nasdaq and went on to serve as a Director of the Nasdaq listed parent and as Australia country representative. Mr. Wells is also a commercial (aircraft) pilot and has served as Chair of two sizable not-for-profit organisations, including Guildford Grammar School. He has bachelor degrees in Law and Commerce and a Diploma of Aviation (L.LB, B.Comm, Dip. Aviation).

Outgoing CEO, Ms. Alison Laws said the following of Mr. Wells' appointment:

"I have worked with Mitchell since 2017 and I'm delighted that he is transitioning into the role of Managing Director of Resonance Health. The Company will progress its strategy for a heightened sales focus and further acceleration of our high impact late-phase R&D projects, with greater

engagement with the capital markets. Mitchell is very well suited to this next phase, and I look forward to continuing my productive relationship with him, as a consultant to Resonance Health."

Chair of Resonance Health, Mr. Martin Blake commented:

"Mitchell joined the Company as a consultant in early 2017 and quickly established himself as an invaluable resource focusing on strategy, legal affairs and investor relations. Within a year of his appointment, we invited him to join the Board of Directors and he has been an outstanding contributor as a Director and consultant. Mitchell played a key role in Alison's appointment as CEO in 2018 which proved a highly successful appointment. Mitchell is approachable, astute, energetic, inclusive, and personable, and the Board looks forward to growth under his stewardship."

Incoming Managing Director, Mr. Mitchell Wells commented:

"I am excited and grateful to be given the opportunity to serve as Managing Director. The Company is at an exciting crossroads thanks to the achievements and hard work of Alison and the competent and committed team at Resonance Health. We are 'launch ready' to market our scalable AI based and recently regulatory cleared medical devices, and we have a pipeline of very high-impact late-phase commercially focused R&D projects. We recently made a significant appointment in Mr. Nick Allan as our CFO, and we are actively recruiting several experienced med-tech sales personnel to lead our global marketing and sales efforts. I look forward to sharing further information about our growth plans with our shareholders and the investment community."

Ms. Laws' final day as CEO of Resonance Health will be Friday 2 July 2021. Following that date, Ms. Laws will provide consultancy services to the Company, as her personal circumstances permit. The Board again thanks Ms. Laws for her outstanding service as CEO and looks forward to working with her as a consultant.

The Board will provide details of Mr. Wells' remuneration in the coming days although it is anticipated that his base salary remuneration will be similar to that of outgoing CEO, Ms. Laws.

This announcement has been authorised by the Board of Directors of the Company.

For further information please contact:

Mitchell Wells – Managing Director, Resonance Health
E: mitchellw@resonancehealth.com P: +61 (0)8 9286 5300; or

Chad Tondut – Communications Manager, Resonance Health
E: chadt@resonancehealth.com P: +61 (0)8 9286 5300